Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.

NCT02353143 is registered in ClinicalTrials.gov with Menarini Group as lead sponsor.

NCT NCT02353143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02353143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.
Lead sponsor
Menarini Group
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2014
Completion date
April 9, 2021
Enrollment
71 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, in relapse, recurrent adult acute myeloid leukemia